Beyond the Spirometry: New Diagnostic Modalities in Chronic Obstructive Pulmonary Disease

Article information

Tuberc Respir Dis. 2025;88(1):1-13

Publication date (electronic) : 2024 September 23

doi : https://doi.org/10.4046/trd.2024.0040

¹Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea

²Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Republic of Korea

Address for correspondence Youlim Kim, M.D., Ph.D. Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, 120-1 Neungdongro, Gwangjin-gu, Seoul 05030, Republic of Korea Phone 82-2-2030-7524 Fax 82-2-2030-7748 E-mail weilin810707@gmail.com

Received 2024 March 22; Revised 2024 June 1; Accepted 2024 September 19.

Abstract

Spirometry can play a critical role as a gold standard in the diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD). While the criteria for diagnosis have advanced over time, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard of the forced expiratory volume in 1 second/forced vital capacity ratio <0.7 remains the most universally employed metric. However, spirometry cannot be utilized in all situations, and test execution can be difficult for some patients, often showing normal values in the early diagnosis of COPD. Therefore, research on new diagnostic methods is underway. Techniques include whole-body plethysmography for measurement of residual volume and inspiratory capacity and airway resistance, diffusing capacity of carbon monoxide or nitric oxide, impulse oscillometry, infrared time-offlight depth image sensor, diaphragm ultrasonography, which can enable early diagnosis and multifaceted assessment of patients with COPD.

Keywords: Chronic Obstructive Pulmonary Disease; Respiratory Function Tests; Oscillometry; Plethysmography; Ultrasonography

Key Figure

Introduction

Chronic obstructive pulmonary disease (COPD) presents a significant global health challenge, affecting millions with this progressive lung condition [1]. Although spirometry is the cornerstone of COPD diagnosis [2], its effectiveness is limited in the early detection of the disease and in patients with performance limitations [2]. Consequently, the integration of complementary pulmonary function tests (PFTs) is essential. Measurements such as the diffusing capacity of the lungs for carbon monoxide (DLCO) [3], airway resistance [4], and respiratory oscillometry [5] offer crucial insights into the manifestations of COPD, including static lung hyperinflation, airway obstruction, and small airway dysfunction, which spirometry alone cannot fully assess [6].

The introduction of these sophisticated diagnostic tools enables a more comprehensive evaluation of lung function, particularly beneficial for characterizing precursor conditions like preserved ratio impaired spirometry (PRISm) [2] and the phenotype of asthma-COPD overlap (ACO). These tools support the development of tailored strategies [7]. Utilizing these modalities can also improve our understanding of disease severity and progression, facilitating personalized management approaches.

The increasing recognition of comprehensive methods for evaluating lung function, given traditional spirometry’s limitations, necessitates clinicians’ knowledge of these constraints and the potential of emerging diagnostic techniques.

The purpose of this review is to examine the role of recently introduced diagnostic tools (Table 1 and Figure 1) [8-30], including hyperinflation quantified by residual volume (RV), single-breath washout (SBW) nitrogen test, airway resistance (Raw) measured by body plethysmography or respiratory oscillometry, infrared timeof-flight (ToF) depth image sensor, ultrasonography of the diaphragm, and respiratory muscle strength. These tools provide valuable insights into gas exchange, airway obstruction, and small airway function, which are critical components of the disease. Enhanced knowledge of spirometry’s limitations and the capabilities of these novel diagnostic modalities can lead to more thorough assessments of patients with COPD, offering guidance on appropriate treatment and management strategies.

Table 1.

Techniques for COPD evaluation

Fig. 1.

Comprehensive assessment of chronic obstructive pulmonary disease; traditional and new methods. DLCO: diffusing capacity of the lung for carbon monoxide; EAFL-SS: expiratory airflow limitation steady state; DLNO: diffusing capacity of the lung for nitric oxide.

Current Diagnosis of COPD

1. The role of spirometry in COPD

During the assessment or treatment of patients with COPD, spirometric data is valuable for diagnosing COPD and for gauging the severity of airflow limitation using forced expiratory volume in 1 second (FEV₁). Patients with irreversible airflow obstruction (post-bronchodilator FEV₁/forced vital capacity [FVC] ratio <0.7) [31], respiratory symptoms, and risk factors such as smoking, occupational exposure, and environmental pollutants are typically diagnosed with COPD [2].

Spirometric data remains an essential tool for healthcare professionals in assessing airflow obstruction and confirming the diagnosis of COPD [2]. Expressing FEV₁ as a percentage of the predicted value in a patient can effectively determine the condition’s severity. Lower FEV₁ [32,33], rapid decline of FEV₁ [34] are considered predictors of a higher risk of COPD exacerbation. Additionally, a lower FEV₁/FVC ratio [35] is associated with all-cause mortality.

2. Evolving criteria for airway obstruction

Airway obstruction was initially defined by the European Community for Steel and Coal and the European Respiratory Society (ERS) as a condition where the FEV₁/FVC ratio falls below the lower fifth percentile of a relatively large healthy reference group, a threshold known as the lower limit of normal (LLN) [36]. A FEV₁/FVC ratio of 0.75 was later established as the cut-off by the American Thoracic Society (ATS) in 1987 [37], and a FEV₁/FVC ratio of 0.70 with FEV₁ <80% was predicted by the British Thoracic Society in 1997 [38]. In 2007, COPD was redefined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as a fixed FEV₁/FVC ratio of less than 0.7, a standard unaffected by factors such as age and gender, and with no limitation on FEV₁ [39]. Despite the potential for a significant number of false-positive results in older non-smokers and false-negative results in younger patients when using the fixed FEV₁/FVC ratio instead of the LLN [40,41], this method has advantages in identifying populations at increased risk of COPD [42].

3. Concerns regarding the use of spirometry in assessing COPD

COPD encompasses several phenotypes beyond the traditional classification of emphysema and chronic bronchitis, including the frequent exacerbator phenotype (two or more acute exacerbations per year) [43], ACO [7], and small airway disease (SAD) [44,45]. These phenotypes play a vital role in predicting patient prognosis and guiding treatment strategies [46]. However, their differential diagnosis using only spirometry remains challenging. Spirometry does not correlate with arterial blood gas, a key predictor of survival in patients with COPD, thus limiting its efficacy [47,48].

New Diagnostic Modalities

1. Use of the RV/total lung capacity, inspiratory capacity/total lung capacity ratio for measuring air trapping (utilizing whole body plethysmography in assessing spirometric parameters)

Whole body plethysmography (WBP) enables clinicians to measure spirometric parameters such as total lung capacity (TLC), RV, inspiratory capacity (IC), and inspiratory reserve volume (IRV). Typically, the normal ranges for TLC, functional residual capacity (FRC), and RV fall between 80% and 120% of the predicted value [4].

Early pathophysiological manifestations of COPD may include air trapping due to limited expiratory airflow, evidenced by an increased FRC or RV (>140% of predicted). Additionally, limited expiratory airflow can lead to lung hyperinflation, denoted by a higher RV/TLC ratio, and reductions in both IC and IRV [4].

Data from two Korean COPD cohorts, the Korean Obstructive Lung Disease (KOLD) Cohort Study and the Korea COPD Subgroup Study (KOCOSS), also indicate a positive correlation between acute exacerbations and RV/TLC [8,9]. COPD patients with a change from a normal to an abnormal RV/TLC exhibited worsened lung function and more severe emphysematous changes on chest computed tomography (CT) [9]. A study found that in chronic hypercapnic COPD patients undergoing noninvasive ventilation (NIV), an increased RV/TLC ratio was a risk factor for all-cause mortality [10].

A reduction in the resting IC or IC/TLC ratio is considered a sensitive indicator of hyperinflation. IC is negatively correlated with FEV₁ [11], suggesting flow limitation in early stages of COPD with preserved FEV₁. An IC/TLC ratio below 25% is associated with decreased exercise capacity, higher mortality, and increased exacerbations in GOLD stage II–III [12], and IC/TLC independently predicted mortality beyond the Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity (BODE) index in a USA and Spanish COPD cohort [11].

While measurements of RV/TLC and IC/TLC can offer significant insights into static lung hyperinflation, they are not as readily performed or practical as spirometry, especially for patients who are unsuitable for traditional spirometry.

2. FRC evaluation using the helium (He) dilution method

The helium dilution method, involving the inhalation of helium mixed with oxygen and allowing it to equilibrate in the lungs, accurately measures FRC—the gas volume remaining in the lungs at the end of a passive expiration [49,50]. This method has been utilized in studies to quantify air trapping in COPD.

A study of 65 COPD patients disclosed that those at higher GOLD stages, indicating more advanced disease, displayed significantly higher FRC values using the single-breath helium dilution method [51]. In another study of 55 COPD patients, D’Ascanio et al. [13] reported that RV/TLC ratios measured by the helium dilution method correlated with those from WBP. The study also linked these measurements to reactance at 5 Hz (X(5)) from oscillometry data, which will be further discussed [13].

3. Closing volume/closing capacity

Closing volume (CV) is the lung volume at which small airways begin to close during expiration, impairing gas exchange by trapping air; closing capacity (CC) is measured as CV+RV [52]. Two methods are used to measure the CV: the xenon gas bolus measurement [53] and the interstitial gas washout method. Due to radiation exposure concerns, the latter is now the most frequently used and is known as the SBW method. In this method, the subject exhales to the RV, inhales pure oxygen up to the TLC, and then exhales through the nitrogen (N₂) sensor. An expirogram comprises four distinct phases: phase I, the absolute dead space; phase II, the bronchial phase; phase III, the alveolar phase; and phase IV [54]. In phase I, N₂ is not detected, but its concentration rises as the phase advances. At the end of expiration (phase IV), nitrogen released from the upper lobe causes an upward shift in N₂ concentration, indicating the point where CC can be measured [14]. In emphysema, structural changes in the lungs lead to increased values of both CV and CC, which correlate with disease severity [55,56].

4. Diffusing capacity, carbon monoxide transfer coefficient or DLCO/alveolar volume

DLCO, or the lung’s capacity to diffuse carbon monoxide (CO), serves as a marker for gas exchange between the alveolar epithelium and the bloodstream [15,57]. In COPD, a reduced DLCO is often linked with the emphysematous type of the disease [15] and diminished exercise capacity [16]. This reduction is typically seen in patients with more severe COPD and is used to predict exercise intolerance [17], elevated risk of mortality [58,59], development of pulmonary hypertension [60], and frequency of exacerbations [59].

An analysis of data from the Genetic Epidemiology of COPD (COPDGene) study revealed a correlation between a 10% predicted decrease in DLCO and worsened symptoms, along with reduced quality of life in COPD patients [57]. This assessment utilized the COPD Assessment Test (CAT) and St. George’s Respiratory Questionnaire (SGRQ), as well as an evaluation of exercise performance through the 6-minute walk distance (6MWD) test. Furthermore, a decline in DLCO was associated with an increased rate of severe exacerbations [57]. A retrospective cohort study involving patients with GOLD stage I COPD from Spain and Canada identified a correlation between a predicted DLCO cut-off value of less than 60% and a higher rate of all-cause mortality. Also reported were worsening symptoms and a decline in 6MWD, a lower IC/TLC ratio, and a higher BODE index in patients with a DLCO <60% [58].

DLCO can decrease as a result of reduced alveolar volume (VA) post-lung resection, indicating that more precise measurement may be achievable by utilizing the DLCO/VA ratio [61]. The CO transfer coefficient (KCO) is determined by the ratio of hemoglobin-adjusted DLCO to VA [61]. KCO serves as an indicator of changes in functional lung volume and impediments to gas exchange across the alveolar-capillary membrane [61]. A decrease in KCO is typically linked to the destruction of lung parenchyma, SAD, and damage to the microvascular system [61].

A study by Shimizu et al. [62], assessed emphysema volumes (lung attenuation volume [%LAV]) and the percentage of cross-sectional area of small pulmonary vessels smaller than 5 mm (%CSA [<5]) via chest CT scans in non-smokers, smokers with asthma, and COPD patients. According to the study’s findings, %KCO demonstrated a stronger correlation with %LAV and %CSA than %DLCO [62]. Data from KOLD also indicated a lower FEV₁/FVC% and a higher emphysema index at baseline for individuals who experienced the most rapid decline in KCO. This group exhibited an increased risk of acute exacerbations [18].

Unlike DLCO, the measurement of nitric oxide diffusing capacity (DLNO), which assesses the diffusion of nitric oxide (NO), does not depend on capillary blood volume [63,64]. Measurement of DLNO is more sensitive to changes in alveolar structure than DLCO, which is influenced by blood flow and anemia [64-66]. The barrier to CO uptake primarily occurs within the red blood cell (RBC), while the barrier to NO diffusion primarily exists between the alveolar membrane and the RBC membrane [67]. DLNO is minimally affected by variations in hemoglobin concentration [68] or oxygenation conditions [69] and serves as an indicator of the diffusing state of the alveolar membrane [70]. Research by van der Lee et al. [19] also found that KNO (DLNO/VA) displays greater sensitivity in diagnosing CT-based emphysema compared to KCO (DLCO/VA) and FEV₁/FVC. However, because of technical challenges, DLNO’s clinical application has been restricted [64,71].

5. ΔN₂ from the single-breath washout test

The nitrogen SBW test was briefly mentioned in the CC section. The phase III slope, or slope of the alveolar plateau (ΔN₂), reflects changes in nitrogen concentration during the nitrogen SBW test. Normally in healthy individuals, this process is uniform, ensuring effective gas exchange [14,72]. In COPD patients, a rapid increase in nitrogen, or a higher ΔN₂, signifies residual N₂ in the lungs at the end of expiration, illustrating air trapping and uneven ventilation [73].

A study conducted by Mikamo et al. [74] reported significant correlations between ΔN₂ and various lung function and structural parameters, including FVC (% predicted), resonant frequency, and emphysema score. Additionally, the Po River Delta epidemiological study, which involved an 8-year longitudinal follow-up, demonstrated a significant association between ΔN₂ measured by the SBW test and the rate of FEV₁ decline, as well as the risk of developing COPD as defined by the GOLD and ATS-ERS criteria [20]. Olofson et al. [75] reported that a steep N₂ slope along with multiple respiratory symptoms, such as dyspnea and wheezing, effectively predicted hospital admissions and mortality in COPD patients.

6. Measurement of airway resistance (Raw) utilizing body plethysmography or respiratory oscillometry

Increased airway resistance is a key pathological component in COPD, and a major site for the development of heightened airway resistance is the small airways [44,76,77].. Technically, airway resistance (Raw) is calculated from the ratio of driving pressure to airflow rate, indicating the alveolar pressure required to achieve a flow rate of 1 L/sec [4]. Using WBP, Raw can be determined by dividing the specific resistance loops (sRaw), which represent the inverse slope of the flow versus box pressure plot, by the FRC measured by plethysmography (FRCpleth) during the occlusion maneuver [4]. In cases of hyperinflation with increased FRC, Raw registers as normal while sRaw is elevated, allowing discrimination from early obstructive lung disease, characterized by increases in both values [4,21].

Impulse oscillometry (IOS), a forced oscillation technique (FOT), represents a significant advancement in the measurement of airway resistance, aiming to overcome existing limitations [78]. IOS, a noninvasive technique, employs sound waves to evaluate respiratory mechanics (Figure 2) [79]. Using IOS eliminates the need for forced expiratory maneuvers and requires minimal patient cooperation, making it a suitable tool for as sessing lung function in populations such aspediatric and elderly patients, for whom traditional spirometry may not be feasible [22,80].

Fig. 2.

Schematic diagram of respiratory oscillometry. Therapeutics & Clinical Risk Management 2020;16:1139-50. Originally published by and used with permission from Dove Medical Press Ltd.

FOT provides detailed insights into the resistive properties of the lungs, such as changes in elastance and lung parenchyma structure. It offers estimations of the impedance of the respiratory system (Zrs), encompassing both resistance (Rrs) and reactance (Xrs) [81]. The principle of IOS involves delivering waves at a consistent and repetitive frequency through a loudspeaker during respiration. The analysis of resultant pressure and flow responses alongside resistance and reactance is achieved using Fourier transformation methods. These responses, reflecting both the forces ahead of the sound wave (resistance) and those produced in response to wave pressure (reactance), reveal the impedance of the entire respiratory system, enabling a passive evaluation of lung mechanics [5].

Several studies [22,80,82,83] have described the clinical utility of IOS in smokers and patients with COPD. One study involving asymptomatic smokers with normal spirometry detected a significant inverse relationship between the values of decreased resistance from 5 to 20 Hz (R5–R20) and the ratio of forced expiratory volume in 3 and 6 seconds (FEV3/FEV6) [22]. Another investigation involving subjects with chronic respiratory symptoms and preserved pulmonary function (PRISm) found that IOS parameters correlated better with symptom scores than spirometric data [23]. There was also a noted increase in R5, R5–R20, the integrated area of low-frequency reactance (AX), and resonance frequency (Fres) in subjects diagnosed with SAD. These findings suggest that IOS might be more sensitive than spirometry in detecting SAD in individuals with chronic respiratory symptoms and preserved pulmonary function; therefore, it could serve as an additional method to identify early-stage SAD [23]. The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) cohort study evaluated the efficacy of IOS in determining COPD severity [24], revealing that abnormalities in AX, R5, and emphysema grades detected by CT scans were more frequently observed in patients categorized as GOLD 2, 3, and 4 [24]. Another study indicated good agreement between values obtained from the FOT and spirometric data in COPD patients. Particularly, reactance (X) values showed high correlation with specific spirometric measures like FEV₁, the forced mid-expiratory flow, and RV/TLC, which are markers of airflow obstruction, SAD, and air trapping. Using Fres and frequency dependence (FDep) allowed for the accurate diagnosis of severe COPD, and varying severities of air trapping could be stratified by X values [82].

7. Infrared time-of-flight depth image sensor

The non-contact early airflow limitation screening system (EAFL-SS), an innovative non-contact screening tool that does not require individual calibration with a spirometer, employs an infrared ToF depth image sensor—a technology widely used in smartphones for applications like photography focusing (Figure 3). The 850 nm infrared ToF sensor, featuring 224×171 pixels, is coupled with custom-designed data processing algorithms to provide real-time, three-dimensional visualization of the anterior-thorax movements [25]. This method, fundamentally akin to photoplethysmography using a remote sensor, does not require separate calibration when adjusted for anthropometric data [84,85].

Fig. 3.

Non-contact early airflow limitation screening system using an infrared (IR) time-of-flight (ToF) depth image sensor. This system creates a three-dimensional (3D) moving image of the examinee’s anterior chest to volume-time curve matching to the region of interest (ROI). Adapted from Takamoto et al. [25]

Calculation of FVC_EAFL-SS is conducted using multiple linear regression analysis, utilizing ToF-derived anterior-thorax FVC, height, and body mass index as explanatory variables, with spirometer-derived FVC as the objective variable. The EAFL-SS system enables tracking of respiration during forced exhalation while in a stationary position, referencing a spirometer. Similar to diagnosing COPD, an FEV_1EAFL-SS/FVC_EAFL-SS ratio below 0.7 suggests airflow obstruction [25]. EAFL-SS demonstrates a sensitivity of 81% and a specificity of 90% in diagnosing COPD and correlates well with spirometric data. The system is user-friendly and universally applicable for initial diagnosis [25].

8. Diaphragm ultrasonographic method

Since the 1970s, M-mode or two-dimensional mode has been employed to study diaphragmatic function for assessing changes in the diaphragm’s thickness during exhalation and deep inhalation. This method is valuable for measuring inspiratory thickening, providing insights into diaphragmatic function quality, and identifying diaphragmatic paralysis or diminished function [86,87].

Some studies have noted inconsistencies in diaphragmatic thickness and variations in the thickening fraction in COPD [88-90]. However, a decrease in diaphragmatic displacement during deep breathing, associated with air trapping and correlated with RV and the RV/TLC, has been observed in moderate to severe cases [90]. This reduction has also been linked to decreased exercise capacity, which typically improves post-rehabilitation [91].

Other studies have assessed the M-mode index of obstruction (MIO) using M-mode ultrasound to examine the right diaphragm during maximal expiratory effort. An MIO lower than 77, calculated as the ratio of maximum expiratory diaphragmatic excursion to the diaphragmatic excursion in the first second of expiration, is associated with obstructive lung disease [26].

The diagnostic potential of diaphragm ultrasonography (DUS) for distinguishing between acute exacerbations of COPD and stable conditions has been acknowledged. A study by An et al. [27] observed reduced thickening fraction and decreased diaphragm excursion in the COPD exacerbation group compared to the stable group. Another study found that approximately 24.3% (10 out of 41) of COPD patients with acute exacerbations exhibited diaphragmatic dysfunction, characterized by a change in diaphragmatic thickness of less than 20% during spontaneous respiration. This dysfunction was significantly associated with clinical failure of NIV, extended intensive care unit stays, pro-longed mechanical ventilation, and the need for tracheostomy [28].

Diaphragm sonography performed during PFT using a mouthpiece and nose clip has been reported to increase excursions, which may differ from the patient’s natural breathing pattern and should be interpreted with caution [86].

9. Inspiratory pressure for respiratory muscle strength

Respiratory muscle strength declines with age [92], a phenomenon also observed in individuals with COPD [93]. Nishimura and colleagues, in their study of 24 male COPD patients, found a significant positive correlation between respiratory muscle strength, as indicated by maximal inspiratory mouth pressure and maximal expiratory mouth pressure, and vital physical parameters such as lean body mass and body weight [94]. In another retrospective study by Kim et al. [29], the COPD group experiencing acute exacerbations exhibited statistically lower maximal inspiratory pressure (MIP) compared to the COPD group without exacerbations. Additionally, as the COPD stage progressed, the MIP values decreased [29].

In a study involving 61 COPD veterans, it was observed that sustained maximal inspiratory pressure (SMIP) correlated better with FEV₁, IC, and the IC/TLC ratio than MIP. Moreover, the SMIP group with less than 427 pressure time units exhibited lower FEV₁, higher RV, higher modified Medical Research Council Dyspnea Scale scores, higher Hospital Anxiety and Depression Scale depression scores, and a higher frequency of previous acute exacerbations [95].

Respiratory muscle strength, as measured by MIP, maximal expiratory pressure (MEP), and SMIP, not only shows a relationship with lung function and acute exacerbations in COPD patients but has also been shown to improve with rehabilitation therapy. In a study of 32 COPD patients, a home-based rehabilitation program led to improvements in MIP and MEP, as well as a reduction in the perception of dyspnea [96].

Multiple Faces of COPD

The traditional view of COPD as a single disease entity has evolved with the recognition of distinct subtypes and phenotypes within the broader spectrum of COPD. These subtypes may include SAD, emphysema, and overlapping conditions such as ACO. Key pathognomonic changes, including structural lung lesions like emphysema or SAD, and physiological changes such as declines in FEV1, air trapping, hyperinflation, and a decrease in lung diffusing capacity, are crucial for understanding the disease processes and tailoring treatment strategies for individual patients [2].

The concept of ‘multiple faces’ encompasses the systemic effects of COPD, including muscle dysfunction, systemic inflammation, and metabolic dysfunction, which contribute to the disease’s heterogeneity [97,98]. Moreover, the patient’s experience of living with COPD, which involves chronic breathlessness and the challenges encountered by patients and their caregivers, underscores the diverse and complex nature of the disease. Although beyond the scope of this article, we recognize the considerable potential for nutritional and morphotypic evaluations in the COPD context.

Conclusion

In conclusion, various diagnostic modalities such as infrared ToF depth image sensor, WBP, DLCO measurement, airway resistance assessment using body plethysmography, respiratory oscillometry, and DUS provide comprehensive insights into the diagnosis and evaluation of COPD patients. These techniques are valuable for early detection, quantifying airflow obstruction, distinguishing airway resistance, and assessing risk, thereby enhancing the understanding of disease presentations and optimizing patient management strategies. Ultimately, this leads to improved quality of life for individuals with COPD and paves the way for developing more effective treatments and interventions in the future.

Notes

Authors’ Contributions

Conceptualization: Kim Y. Methodology: Kim Y. Formal analysis: Song JH. Data curation: all authors. Project administration: Kim Y. Visualization: all authors. Software: all authors. Validation: Kim Y. Investigation: Song JH. Writing - original draft preparation: all authors. Writing - review and editing: Kim Y. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Funding

No funding to declare.

Acknowledgements

Seou Kim provided medical illustrations for this article.

References

1. Halpin DM, Celli BR, Criner GJ, Frith P, Lopez Varela MV, Salvi S, et al. The GOLD summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis 2019;23:1131–41.

2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2024 report. Deer Park: GOLD; 2024.

3. Blakemore WS, Forster RE, Morton JW, Ogilvie CM. A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957;36(1 Part 1):1–17.

4. Criee CP, Sorichter S, Smith HJ, Kardos P, Merget R, Heise D, et al. Body plethysmography: its principles and clinical use. Respir Med 2011;105:959–71.

5. Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003;22:1026–41.

6. Kakavas S, Kotsiou OS, Perlikos F, Mermiri M, Mavrovounis G, Gourgoulianis K, et al. Pulmonary function testing in COPD: looking beyond the curtain of FEV1. NPJ Prim Care Respir Med 2021;31:23.

7. Tu X, Donovan C, Kim RY, Wark PA, Horvat JC, Hansbro PM. Asthma-COPD overlap: current understanding and the utility of experimental models. Eur Respir Rev 2021;30:190185.

8. Kim Y, Kim SH, Rhee CK, Lee JS, Lee CY, Kim DK, et al. Air trapping and the risk of COPD exacerbation: analysis from prospective KOCOSS cohort. Front Med (Lausanne) 2022;9:835069.

9. Lim JU, Lee JS, Lee JH, Lee SD, Oh YM, Rhee CK, et al. Clinical impact of long-term change in air trapping on pulmonary function and computed tomography parameters in chronic obstructive pulmonary disease. Korean J Intern Med 2021;36:636–46.

10. Budweiser S, Jorres RA, Riedl T, Heinemann F, Hitzl AP, Windisch W, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest 2007;131:1650–8.

11. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591–7.

12. Albuquerque AL, Nery LE, Villaca DS, Machado TY, Oliveira CC, Paes AT, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J 2006;28:939–44.

13. D’Ascanio M, Viccaro F, Calabro N, Guerrieri G, Salvucci C, Pizzirusso D, et al. Assessing static lung hyperinflation by whole-body plethysmography, helium dilution, and Impulse Oscillometry System (IOS) in Patients with COPD. Int J Chron Obstruct Pulmon Dis 2020;15:2583–9.

14. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J 2013;41:507–22.

15. Gould GA, Redpath AT, Ryan M, Warren PM, Best JJ, Flenley DC, et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 1991;4:141–6.

16. Behnia M, Wheatley C, Avolio A, Johnson B. Influence of resting lung diffusion on exercise capacity in patients with COPD. BMC Pulm Med 2017;17:117.

17. Farkhooy A, Janson C, Arnardottir RH, Malinovschi A, Emtner M, Hedenstrom H. Impaired carbon monoxide diffusing capacity is the strongest predictor of exercise intolerance in COPD. COPD 2013;10:180–5.

18. Kim YW, Lee CH, Hwang HG, Kim YI, Kim DK, Oh YM, et al. Decline in carbon monoxide transfer coefficient in chronic obstructive pulmonary disease. J Clin Med 2020;9:1512.

19. van der Lee I, Gietema HA, Zanen P, van Klaveren RJ, Prokop M, Lammers JW, et al. Nitric oxide diffusing capacity versus spirometry in the early diagnosis of emphysema in smokers. Respir Med 2009;103:1892–7.

20. Pistelli F, Sherrill DL, Di Pede F, Baldacci S, Simoni M, Maio S, et al. Single breath nitrogen test as predictor of lung function decline and COPD over an 8-year follow-up. Pulmonology 2024;30:546–54.

21. Mahut B, Caumont-Prim A, Plantier L, Gillet-Juvin K, Callens E, Sanchez O, et al. Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2012;7:165–71.

22. Pisi R, Aiello M, Frizzelli A, Calzetta L, Marchi L, Bertorelli G, et al. Detection of small airway dysfunction in asymptomatic smokers with preserved spirometry: the value of the impulse oscillometry system. Int J Chron Obstruct Pulmon Dis 2021;16:2585–90.

23. Li LY, Yan TS, Yang J, Li YQ, Fu LX, Lan L, et al. Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function. Respir Res 2021;22:68.

24. Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011;105:1069–78.

25. Takamoto H, Nishine H, Sato S, Sun G, Watanabe S, Seokjin K, et al. Development and clinical application of a novel non-contact early airflow limitation screening system using an infrared time-of-flight depth image sensor. Front Physiol 2020;11:552942.

26. Zanforlin A, Smargiassi A, Inchingolo R, di Marco Berardino A, Valente S, Ramazzina E. Ultrasound analysis of diaphragm kinetics and the diagnosis of airway obstruction: the role of the M-mode index of obstruction. Ultrasound Med Biol 2014;40:1065–71.

27. An TJ, Yoo YJ, Lim JU, Seo W, Park CK, Rhee CK, et al. Diaphragm ultrasound is an imaging biomarker that distinguishes exacerbation status from stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2022;17:3–12.

28. Antenora F, Fantini R, Iattoni A, Castaniere I, Sdanganelli A, Livrieri F, et al. Prevalence and outcomes of diaphragmatic dysfunction assessed by ultrasound technology during acute exacerbation of COPD: a pilot study. Respirology 2017;22:338–44.

29. Kim NS, Seo JH, Ko MH, Park SH, Kang SW, Won YH. Respiratory muscle strength in patients with chronic obstructive pulmonary disease. Ann Rehabil Med 2017;41:659–66.

30. Enright Md P. Office-based DLCO tests help pulmonologists to make important clinical decisions. Respir Investig 2016;54:305–11.

31. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741–50.

32. Zhudenkov K, Palmer R, Jauhiainen A, Helmlinger G, Stepanov O, Peskov K, et al. Longitudinal FEV1 and exacerbation risk in COPD: quantifying the association using joint modelling. Int J Chron Obstruct Pulmon Dis 2021;16:101–11.

33. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847–52.

34. Seemungal TA, Wedzicha JA. Exacerbation frequency and FEV1 decline of COPD: is it geographic? Eur Respir J 2014;43:1220–2.

35. Bhatt SP, Nakhmani A, Fortis S, Strand MJ, Silverman EK, Sciurba FC, et al. FEV1/FVC severity stages for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2023;208:676–84.

36. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6 Suppl 16:5–40.

37. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987;136:225–44.

38. The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52 Suppl 5:S1–28.

39. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Deer Park: GOLD; 2007.

40. Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, et al. GOLD or lower limit of normal definition?: a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 2012;13:13.

41. Roberts SD, Farber MO, Knox KS, Phillips GS, Bhatt NY, Mastronarde JG, et al. FEV1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. Chest 2006;130:200–6.

42. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62:237–41.

43. Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. Chest 2018;153:1106–15.

44. Singh D. Small airway disease in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul) 2017;80:317–24.

45. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med 2014;2:497–506.

46. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598–604.

47. Shibel EM, Moser KM. The relation between spirometric measurements and arterial blood gas analysis in patients with chronic airflow obstruction. Thorax 1970;25:598–603.

48. Emerman CL, Connors AF, Lukens TW, Effron D, May ME. Relationship between arterial blood gases and spirometry in acute exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1989;18:523–7.

49. Meneely GR, Kaltreider NL. The volume of the lung determined by helium dilution: description of the method and comparison with other procedures. J Clin Invest 1949;28:129–39.

50. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511–22.

51. Jarenback L, Ankerst J, Bjermer L, Tufvesson E. Flow-volume parameters in COPD related to extended measurements of lung volume, diffusion, and resistance. Pulm Med 2013;2013:782052.

52. Milic-Emili J, Torchio R, D’Angelo E. Closing volume: a reappraisal (1967-2007). Eur J Appl Physiol 2007;99:567–83.

53. Dollfuss RE, Milic-Emili J, Bates DV. Regional ventilation of the lung, studied with boluses of 133xenon. Respir Physiol 1967;2:234–46.

54. Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration 2009;78:339–55.

55. Garland A, Hopton P. Airway closure in anaesthesia and intensive care. BJA Educ 2022;22:126–30.

56. Drummond GB, Milic-Emili J. Forty years of closing volume. Br J Anaesth 2007;99:772–4.

57. Balasubramanian A, MacIntyre NR, Henderson RJ, Jensen RL, Kinney G, Stringer WW, et al. Diffusing capacity of carbon monoxide in assessment of COPD. Chest 2019;156:1111–9.

58. de-Torres JP, O’Donnell DE, Marin JM, Cabrera C, Casanova C, Marin M, et al. Clinical and prognostic impact of low diffusing capacity for carbon monoxide values in patients with global initiative for obstructive lung disease I COPD. Chest 2021;160:872–8.

59. Choi J, Sim JK, Oh JY, Lee YS, Hur GY, Lee SY, et al. Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1). BMC Pulm Med 2021;21:152.

60. Balasubramanian A, Kolb TM, Damico RL, Hassoun PM, McCormack MC, Mathai SC. Diffusing capacity is an independent predictor of outcomes in pulmonary hypertension associated with COPD. Chest 2020;158:722–34.

61. Hughes JM, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med 2012;186:132–9.

62. Shimizu K, Konno S, Makita H, Kimura H, Kimura H, Suzuki M, et al. Transfer coefficients better reflect emphysematous changes than carbon monoxide diffusing capacity in obstructive lung diseases. J Appl Physiol (1985) 2018;125:183–9.

63. Tamhane RM, Johnson RL Jr, Hsia CC. Pulmonary membrane diffusing capacity and capillary blood volume measured during exercise from nitric oxide uptake. Chest 2001;120:1850–6.

64. Zavorsky GS, Hsia CC, Hughes JM, Borland CD, Guenard H, van der Lee I, et al. Standardisation and application of the single-breath determination of nitric oxide uptake in the lung. Eur Respir J 2017;49:1600962.

65. Hughes JM, Dinh-Xuan AT. The DLNO/DLCO ratio: physiological significance and clinical implications. Respir Physiol Neurobiol 2017;241:17–22.

66. Barisione G, Brusasco V. Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19. Physiol Rep 2021;9e14748.

67. Borland C, Bottrill F, Jones A, Sparkes C, Vuylsteke A. The significant blood resistance to lung nitric oxide transfer lies within the red cell. J Appl Physiol (1985) 2014;116:32–41.

68. van der Lee I, Zanen P, Biesma DH, van den Bosch JM. The effect of red cell transfusion on nitric oxide diffusing capacity. Respiration 2005;72:512–6.

69. Guenard HJ, Martinot JB, Martin S, Maury B, Lalande S, Kays C. In vivo estimates of NO and CO conductance for haemoglobin and for lung transfer in humans. Respir Physiol Neurobiol 2016;228:1–8.

70. Zavorsky GS, van der Lee I. Can the measurement of pulmonary diffusing capacity for nitric oxide replace the measurement of pulmonary diffusing capacity for carbon monoxide? Respir Physiol Neurobiol 2017;241:9–16.

71. Giraud X, Le-Dong NN, Hogben K, Martinot JB. The measurement of DLNO and DLCO: a manufacturer’s perspective. Respir Physiol Neurobiol 2017;241:36–44.

72. Fowler WS. Lung function studies; uneven pulmonary ventilation in normal subjects and in patients with pulmonary disease. J Appl Physiol 1949;2:283–99.

73. Boeck L, Gensmer A, Nyilas S, Stieltjes B, Re TJ, Tamm M, et al. Single-breath washout tests to assess small airway disease in COPD. Chest 2016;150:1091–100.

74. Mikamo M, Shirai T, Mori K, Shishido Y, Akita T, Morita S, et al. Predictors of phase III slope of nitrogen single-breath washout in COPD. Respir Physiol Neurobiol 2013;189:42–6.

75. Olofson J, Bake B, Bergman B, Vanfleteren LE, Svardsudd K. Prediction of COPD by the single-breath nitrogen test and various respiratory symptoms. ERJ Open Res 2021;7:00383–2021.

76. Higham A, Quinn AM, Cancado JE, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res 2019;20:49.

77. Stockley JA, Cooper BG, Stockley RA, Sapey E. Small airways disease: time for a revisit? Int J Chron Obstruct Pulmon Dis 2017;12:2343–53.

78. Landser FJ, Nagles J, Demedts M, Billiet L, van de Woestijne KP. A new method to determine frequency characteristics of the respiratory system. J Appl Physiol 1976;41:101–6.

79. Porojan-Suppini N, Fira-Mladinescu O, Marc M, Tudorache E, Oancea C. Lung function assessment by impulse oscillometry in adults. Ther Clin Risk Manag 2020;16:1139–50.

80. Tomalak W, Czajkowska-Malinowska M, Radlinski J. Application of impulse oscillometry in respiratory system evaluation in elderly patients. Pneumonol Alergol Pol 2014;82:330–5.

81. Desiraju K, Agrawal A. Impulse oscillometry: the state-ofart for lung function testing. Lung India 2016;33:410–6.

82. Tse HN, Tseng CZ, Wong KY, Yee KS, Ng LY. Accuracy of forced oscillation technique to assess lung function in geriatric COPD population. Int J Chron Obstruct Pulmon Dis 2016;11:1105–18.

83. Jetmalani K, Thamrin C, Farah CS, Bertolin A, Chapman DG, Berend N, et al. Peripheral airway dysfunction and relationship with symptoms in smokers with preserved spirometry. Respirology 2018;23:512–8.

84. Soleimani V, Mirmehdi M, Damen D, Camplani M, Hannuna S, Sharp C, et al. Depth-based whole body photoplethysmography in remote pulmonary function testing. IEEE Trans Biomed Eng 2018;65:1421–31.

85. Soleimani V, Mirmehdi M, Damen D, Dodd J, Hannuna S, Sharp C, et al. Remote, depth-based lung function assessment. IEEE Trans Biomed Eng 2017;64:1943–58.

86. Santana PV, Cardenas LZ, Albuquerque AL, Carvalho CR, Caruso P. Diaphragmatic ultrasound: a review of its methodological aspects and clinical uses. J Bras Pneumol 2020;46e20200064.

87. Boussuges A, Gole Y, Blanc P. Diaphragmatic motion studied by m-mode ultrasonography: methods, reproducibility, and normal values. Chest 2009;135:391–400.

88. Baria MR, Shahgholi L, Sorenson EJ, Harper CJ, Lim KG, Strommen JA, et al. B-mode ultrasound assessment of diaphragm structure and function in patients with COPD. Chest 2014;146:680–5.

89. Smargiassi A, Inchingolo R, Tagliaboschi L, Di Marco Berardino A, Valente S, Corbo GM. Ultrasonographic assessment of the diaphragm in chronic obstructive pulmonary disease patients: relationships with pulmonary function and the influence of body composition: a pilot study. Respiration 2014;87:364–71.

90. Dos Santos Yamaguti WP, Paulin E, Shibao S, Chammas MC, Salge JM, Ribeiro M, et al. Air trapping: the major factor limiting diaphragm mobility in chronic obstructive pulmonary disease patients. Respirology 2008;13:138–44.

91. Paulin E, Yamaguti WP, Chammas MC, Shibao S, Stelmach R, Cukier A, et al. Influence of diaphragmatic mobility on exercise tolerance and dyspnea in patients with COPD. Respir Med 2007;101:2113–8.

92. Summerhill EM, Angov N, Garber C, McCool FD. Respiratory muscle strength in the physically active elderly. Lung 2007;185:315–20.

93. Orozco-Levi M. Structure and function of the respiratory muscles in patients with COPD: impairment or adaptation? Eur Respir J Suppl 2003;46:41s–51s.

94. Nishimura Y, Tsutsumi M, Nakata H, Tsunenari T, Maeda H, Yokoyama M. Relationship between respiratory muscle strength and lean body mass in men with COPD. Chest 1995;107:1232–6.

95. Formiga MF, Vital I, Urdaneta G, Campos MA, Cahalin LP. Beyond inspiratory muscle strength: clinical utility of single-breath work capacity assessment in veterans with COPD. Respir Med 2019;147:13–8.

96. Battaglia E, Fulgenzi A, Ferrero ME. Rationale of the combined use of inspiratory and expiratory devices in improving maximal inspiratory pressure and maximal expiratory pressure of patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2009;90:913–8.

97. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008;31:492–501.

98. Benz E, Trajanoska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev 2019;28:190049.

Article information Continued

It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Test	Parameter	Changes in COPD	Strength	Limitation	Reference
Whole body plethysmography/Helium dilution method	RV/TLC	Increase in early airflow limitation	Early detection of airway change	Utilization challenges due to heavy system	[8-10,13]
Whole body plethysmography/Helium dilution method	RV/TLC	Related to exacerbation, emphysema extent, and mortality	Early detection of airway change	Utilization challenges due to heavy system	[8-10,13]
Whole body plethysmography	IC/TLC	Decrease in hyperinflation			[11,12]
Whole body plethysmography	IC/TLC	Related to mortality			[11,12]
Whole body plethysmography	Airway resistance (Raw)	Correlates FEV₁ and RV/TLC			[21]
Diffusing capacity	DLCO	Decreased status related to exercise intolerance, worse symptom, increased risk of exacerbation, and extent of emphysema	Require less effort compared to spirometry tests [30]	Limited access	[15-17]
	KCO (DLCO/VA)	Rapid decline correlated with lower FEV₁/FVC and increased risk of acute exacerbations			[18]
	DLNO	Decreased DLNO correlated with emphysema extent in smokers	Not affected by anemia or blood flow	Limited access	[19]
Nitrogen SBW	ΔN₂	Associated with RV/TLC, FEV₁ decline and risk of developing COPD	Detection of early lung damage	Limited access	[14,20]
IOS	R5	Increase in both central and peripheral airway diseases	Requiring minimal patient cooperation	Limited access	[24]
			Detection of small airway disease
			Evaluation of airway resistance
	R5–R20 (frequency dependence of resistance)	Increase in small airway diseases and mild smokers			[22,23]
	Reactance (X, AX)	Increase in small airway disease			[24]
	Reactance (X, AX)	Correlates spirometric data			[24]
	Fres	Increase in COPD			[24]
EAFL-SS	FEV_1EAFL-SS/FVC_EAFL-SS	Less than 0.7 indicates airflow obstruction	Non-contact technique	Limited access and requires calibration and validation in a larger population	[25]
Diaphragm ultrasonography	ΔTdi	Less than 20% change means diaphragmatic dysfunction, correlates clinical failure of AE-COPD	Noninvasive method	Subjective and requires a trained examiner	[28]
	DEmax	Reduced in exacerbation			[27]
	TFmax	Decreased in exacerbation			[27]
	MIO, calculated as EDE_Max/FEDE1	Lower than 77 associated with obstructive lung disease			[26]
Respiratory muscle strength	MIP	Decreased in severe COPD			[29]